Developing a novel class of cancer therapeutics for solid tumors.

Resolute Science is a San Diego-based biotechnology company advancing a pipeline of first-in-class synthetic drug conjugates for the treatment of solid tumors, including some of the most aggressive forms of cancer.

Many solid tumors are comprised of up to 30-50% of tumor-associated macrophages (TAMs) – non-cancerous immune cells that promote tumor growth and metastasis. Resolute’s Macrophage-Targeted Conjugates (MAC-TACs) harness the natural biology of TAMs to receive, process, and deliver cytotoxic or radiotherapeutic payloads to neighboring cancer cells.

Resistance in cancer often arises when tumor cells lose or mutate the targeted receptor. TAMs are a stable, largely non-dividing cell population that consistently express our targeted receptor. By targeting TAMs instead of cancer cells, MAC-TACs bypass common resistance mechanisms and offer a new treatment option for patients who no longer respond to conventional therapies.

The deadliest and most treatment-resistant cancers are characterized by a high percentage of TAMs. MAC-TACs use TAMs as druggable targets, making aggressive cancers highly treatable.

RS-5, our lead therapeutic candidate, is advancing rapidly toward the clinic. It has shown powerful and consistent anti-cancer efficacy across 22 preclinical studies in 10 tumor models, while being well tolerated in all.